CiMaas develops immunotherapy for cancer by optimally engaging the immune system.
CiMaas moves it's clinical production site to InSciTe in Sittard-Geleen. Working together in the Biomedical Accelerator Matrix, CiMaas and InSciTe are joining forces to bring a cure for cancer one step closer to reality.
Mr T. Beurskens (Representative Province Limburg on Economy and Knowledge infrastructure) visited CiMaas together with Mrs M. Poulssen (policy advisor Economy and Innovation), Mr M. Cobben (personal assistant) to see current state-of-the-art developments in cell therapy for cancer.
MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V. invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.